Business Context and Reporting Period
Company: India Globalization Capital, Inc. (IGC Pharma, Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: January 13, 2021
Event: Entry into a Material Definitive Agreement (ATM Sales Agreement).
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. It details a financing arrangement with the following parameters:
- Offering Size: Up to $75,000,000 of common stock.
- Sales Agent: The Benchmark Company, LLC.
- Commission: 2.5% of gross proceeds.
- Expense Reimbursement: Up to $16,500 for legal counsel fees.
Material Changes
The Company entered into a Sales Agreement to conduct an "at the market" offering. This agreement allows for the issuance and sale of shares directly on the NYSE American or through market makers. The filing references a shelf registration statement (Form S-3) declared effective on January 4, 2021, and a prospectus supplement filed on January 13, 2021.
Guidance, Outlook, and Risks
Management Commentary: The Company retains the right to suspend the offering upon notice. The agreement includes customary representations, warranties, and covenants, along with indemnification provisions for the Sales Agent.
Risks/Contingencies: The filing explicitly states it is not an offer to sell securities in any state where such an offer would be unlawful prior to registration. Sales are subject to market conditions and the Company's discretion to suspend the program.
Investor Verification Checklist
- Verify the current share price and potential dilution impact of a $75 million offering.
- Review the full text of the Sales Agreement (Exhibit 10.1) for specific termination rights and conditions.
- Confirm the status of the underlying Form S-3 Registration Statement (File No. 333-251654).
- Monitor future filings for actual sales volumes and proceeds generated under this agreement.